This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids

This study has been completed.
Information provided by:
Genelabs Technologies Identifier:
First received: May 11, 2004
Last updated: January 10, 2008
Last verified: January 2008
Open label safety and efficacy follow-up.

Condition Intervention Phase
Systemic Lupus Erythematosus Drug: Prasterone (GL701) Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-Center, Open-Label Study to Assess the Durability and Safety of the Prevention of Bone Loss by Treatment With GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids

Resource links provided by NLM:

Further study details as provided by Genelabs Technologies:

Primary Outcome Measures:
  • Maintenance of bone mineral density (BMD) in women with systemic lupus erythematosus receiving glucocorticoids. [ Time Frame: 12 months ]

Enrollment: 114
Study Start Date: July 2003
Study Completion Date: August 2005
Primary Completion Date: August 2005 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Prasterone (GL701)

    There were 4 arms to the study:

    During a previous 6 month db RCT, patients received either prasterone 200 mg/day or placebo. Upon entry into this open-label study, they were re-assigned by randomized allocation to receive either prasterone 200 mg/day or 100 mg/day. Hence, there were 4 possible treatment arms extending over the 18 months of observation between the double-blind study and the subsequent 12 month open-label extension study.

Detailed Description:
This was a randomized, multi-center, open-label, parallel-group, trial of prasterone 200 or 100 mg/day for 12 months in women with lupus receiving glucocorticoid therapy who had completed an earlier 6-month randomized, placebo-controlled study (NCT00053560. Bone Mineral Density assessments were performed at baseline and at months 6 and 12.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient has completed the full 6 month treatment period with study drug in the previous Genelabs' clinical study GL02-01.
  • Concomitant treatment with prednisone (or equivalent) at a dose of ≥ 5mg/day.
  • Patient has read and signed an Informed Consent Form. If the patient is not fluent in English, the Informed Consent must be signed in her native language.

Exclusion Criteria:

  • Patient has had a serious study drug related adverse reaction at any time during the previous GL02-01 study.
  • Any condition which in the Investigator's or Sponsor's opinion is sufficient to prevent adequate compliance with the study or likely to confuse follow-up evaluation (e.g., alcoholism, drug addiction, acute withdrawal from chemical dependency, psychiatric disease).


  • Calcitonin
  • Bisphosphonates
  • Fluoride at pharmacologic dose
  • Strontium at pharmacologic dose
  • Estrogenic steroids (except oral contraceptives)
  • Selective Estrogen Receptor Modulator (raloxifene)
  • Parathyroid hormone
  • Any androgens, including prescription or nutritional supplement DHEA, other than study drug
  • Additional Calcium supplements other than those prescribed as part of this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00082511

United States, Arizona
University of Arizona
Tucson, Arizona, United States, 85724
United States, California
Wallace Rheumatic Study Center
Los Angeles, California, United States, 90048
Lifestyles Health Science Center
Rancho Mirage, California, United States, 92270
University of California San Diego
San Diego, California, United States, 92093-0943
East Bay Rheumatology Group
San Leandro, California, United States, 94578
United States, Florida
Center for Rheumatology, Immunology and Arthritis
Fort Lauderdale, Florida, United States, 33334
Rheumatology Associates of Central Florida
Orlando, Florida, United States, 32806-6264
Tampa Medical Group, P.A.
Tampa, Florida, United States, 33614
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21205
United States, Missouri
St. John's Medical Research Group
Springfield, Missouri, United States, 65804
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, New York
Albert Einstein Medical School
Bronx, New York, United States, 10461
SUNY Downstate Medical Center
Brooklyn, New York, United States, 11203
North Shore University Hospital, Division of Rheumatology
Manhasset, New York, United States, 11030
United States, Oklahoma
Oklahoma Center for Arthritis Therapy
Tulsa, Oklahoma, United States, 74114
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97201
United States, Pennsylvania
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States, 16635
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15261
United States, Virginia
Sentara Medical Group DBA
Virginia Beach, Virginia, United States, 23462
United States, Washington
Seattle Rheumatology Associates
Seattle, Washington, United States, 98104
Immunology/Rheumatology Instituto Nacional de Ciencias Medicas y Nutricion, S.Z.
Mexico City, Mexico, 14000
Sponsors and Collaborators
Genelabs Technologies
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Kenneth E. Schwartz, MD, Genelabs Technologies, Inc. Identifier: NCT00082511     History of Changes
Other Study ID Numbers: GL03-01
Study First Received: May 11, 2004
Last Updated: January 10, 2008

Keywords provided by Genelabs Technologies:
Systemic Lupus Erythematosus
Bone Loss

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Adjuvants, Immunologic
Immunologic Factors processed this record on September 21, 2017